이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Catalent 미래 성장

Future 기준 확인 3/6

Catalent (는) 각각 연간 82.6% 및 5.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 83.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.4% 로 예상됩니다.

주요 정보

98.4%

수익 성장률

104.1%

EPS 성장률

Pharmaceuticals 수익 성장	19.4%
매출 성장률	6.8%
향후 자기자본 수익률	9.0%
애널리스트 커버리지	Good
마지막 업데이트	27 Sep 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

BMV:CTLT * - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	5,380	361	N/A	N/A	1
6/30/2026	5,056	152	N/A	N/A	8
6/30/2025	4,692	41	39	482	9
6/30/2024	4,381	-1,043	-59	268	N/A
3/31/2024	4,135	-1,176	-123	250	N/A
12/31/2023	4,098	-1,302	-263	174	N/A
9/30/2023	4,223	-1,015	-235	276	N/A
6/30/2023	4,263	-256	-322	254	N/A
3/31/2023	4,495	21	-563	127	N/A
12/31/2022	4,731	389	-371	329	N/A
9/30/2022	4,799	399	-471	184	N/A
6/30/2022	4,802	483	-221	439	N/A
3/31/2022	4,703	485	-110	504	N/A
12/31/2021	4,483	561	-183	441	N/A
9/30/2021	4,177	544	-244	446	N/A
6/30/2021	3,998	529	-253	433	N/A
3/31/2021	3,757	494	-188	471	N/A
12/31/2020	3,465	289	-135	518	N/A
9/30/2020	3,275	250	22	565	N/A
6/30/2020	3,094	173	-26	440	N/A
3/31/2020	2,872	104	-37	356	N/A
12/31/2019	2,729	124	20	309	N/A
9/30/2019	2,631	138	-22	232	N/A
6/30/2019	2,518	132	30	248	N/A
3/31/2019	2,478	149	75	263	N/A
12/31/2018	2,488	136	108	283	N/A
9/30/2018	2,471	65	160	332	N/A
6/30/2018	2,463	84	198	375	N/A
3/31/2018	2,395	63	N/A	371	N/A
12/31/2017	2,300	70	N/A	380	N/A
9/30/2017	2,177	109	N/A	335	N/A
6/30/2017	2,075	110	N/A	300	N/A
3/31/2017	1,991	106	N/A	233	N/A
12/31/2016	1,896	91	N/A	180	N/A
9/30/2016	1,867	104	N/A	159	N/A
6/30/2016	1,848	112	N/A	155	N/A
3/31/2016	1,826	207	N/A	199	N/A
12/31/2015	1,835	228	N/A	243	N/A
9/30/2015	1,836	244	N/A	257	N/A
6/30/2015	1,831	212	N/A	172	N/A
3/31/2015	1,840	86	N/A	180	N/A
12/31/2014	1,847	62	N/A	138	N/A
9/30/2014	1,832	-3	N/A	113	N/A
6/30/2014	1,828	19	N/A	178	N/A
3/31/2014	1,813	2	N/A	148	N/A
12/31/2013	1,807	-20	N/A	152	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CTLT * 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 7.7% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: CTLT * (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: CTLT * 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: CTLT * 의 수익(연간 6.9% ) MX 시장( 7% 보다 느리게 성장할 것으로 예상됩니다. 7% 연간).

고성장 수익: CTLT * 의 수익(연간 5.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CTLT * 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 7.4 %).

Catalent 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

President recently sold Mex$1.6m worth of stock

Insufficient new directors

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold Mex$1.3m worth of stock

Investor sentiment deteriorates as stock falls 36%

Investor sentiment improves as stock rises 50%

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Danaher Reportedly Expresses Takeover Interest in Catalent

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Insider recently sold Mex$796k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold Mex$3.2m worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Now 22% undervalued

Investor sentiment deteriorated over the past week

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Investor sentiment deteriorated over the past week

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Executive Chair of the Board recently sold Mex$80m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Catalent, Inc. Announces Board Changes

Insider recently sold Mex$251k worth of stock

Insider recently sold Mex$251k worth of stock

Insufficient new directors

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022